ArticleJournal of virology1998
Regions of human immunodeficiency virus type 1 nef required for function in vivo.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- HIV-1 Env and Nef Cooperatively Contribute to Plasmacytoid Dendritic Cell Activation via CD4-Dependent Mechanisms.Journal of virology · 2015Article
- In vivo analysis of Nef's role in HIV-1 replication, systemic T cell activation and CD4(+) T cell loss.Retrovirology · 2015Article
- Studies of retroviral infection in humanized mice.Virology · 2015Review
- Heterologous Src homology 4 domains support membrane anchoring and biological activity of HIV-1 Nef.The Journal of biological chemistry · 2014Article
- Molecular requirements for T cell recognition of N-myristoylated peptides derived from the simian immunodeficiency virus Nef protein.Journal of virology · 2013Article
- Review
- Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes.Retrovirology · 2012Article
- The Nef-infectivity enigma: mechanisms of enhanced lentiviral infection.Current HIV research · 2011Review
- Article
- Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.PloS one · 2007Article
- Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo.Journal of virology · 2007Review
- Primary human immunodeficiency virus type 1 nef alleles show major differences in pathogenicity in transgenic mice.Journal of virology · 2007Article
- Human immunodeficiency virus Nef induces rapid internalization of the T-cell coreceptor CD8alphabeta.Journal of virology · 2005Article
- Effect of polypurine tract (PPT) mutations on human immunodeficiency virus type 1 replication: a virus with a completely randomized PPT retains low infectivity.Journal of virology · 2005Article
- Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity.Journal of virology · 2004Article
- HIV-1 replication and pathogenesis in the human thymus.Current HIV research · 2003Review
- Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis.Journal of virology · 2003Article
- Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice.Journal of virology · 2001Article
- The pathogenicity of human immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is abolished by mutation of its SH3-binding domain, and disease development is delayed in the absence of Hck.Journal of virology · 2001Article
- Separation of human immunodeficiency virus type 1 replication from nef-mediated pathogenesis in the human thymus.Journal of virology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
In vivo studies in monkeys and humans have indicated that immunodeficiency viruses with Nef deleted are nonpathogenic in immunocompetent hosts, and this has motivated a search for live attenuated vaccine candidates. However, the mechanisms of action of Nef remain elusive. To define the regions of human immunodeficiency virus type 1 (HIV-1) Nef which mediate in vivo pathogenicity, a series of mutated isogenic viruses were inoculated into human thymic implants in SCID-hu mice. Mutation of several regions, including the myristoylation site at the second glycine and a region encompassing amino acids 41 through 49 of Nef, profoundly affected pathogenicity. Surprisingly, mutations of prolines in either of the two distant PXXP SH3 binding domains did not affect pathogenicity, indicating that these regions are not required for Nef activity in developing T-lineage cells. These data suggest that some functions of Nef described in vitro may not be relevant for in vivo pathogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.